🚀 Exciting News from ACROBiosystems! 🚀 We are thrilled to unveil our new state-of-the-art GMP facility, purpose-built to tackle the unique challenges of the cell and gene therapy (CGT) sector with our Resilient Supply brand—your assurance of flexible, high-quality solutions coupled with steadfast global supply and comprehensive regulatory support. Resilient Highlights: - Robust Global Supply: Multi-point distribution ensures continuous availability. - Regulatory Excellence: Compliant with EU, US, and China regulations for unparalleled reliability. - Advanced GMP Quality Management: Upholds superior standards - Cost-effective outcomes. From immunotherapy and stem cells to organoids, we offer innovative products like: - CelThera™ GMP T Cell Expansion Medium - iPSC Culture Solution Laminin 511 Mix & Go ECM Protein - GMP-grade DLL4 Protein for feeder-free NK cell differentiation - Regulatory-compliant rapid test kits, fully validated, significantly shortening cell therapy drug release cycles Our Resilient Supply products and solutions cover the entire drug development process from early discovery, process development and production, characterization and quality control, and safety testing, to clinical research. #CGT #CellTherapy #GeneTherapy #GMP #Biotechnology #Innovation #ACROBiosystems
ACROBiosystems
Biotechnology Research
Newark, Delaware 27,928 followers
Where Proteins and Innovation Advance Biomedicine
About us
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.
- Website
-
http://www.acrobiosystems.com
External link for ACROBiosystems
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Newark, Delaware
- Type
- Public Company
- Founded
- 2010
- Specialties
- Proprietary HEK293 expression platform, In-house developed enzymatic and chemical biotin labeling technique, covid-19 antigens and antibodies, CAR-T, Reagents for COVID-19 vaccine development and evaluation, SARS-CoV-2 Related Kit Products, Targets for Antibody-Drug Conjugates, Hot target for bispecific antibody, CD3, Bispecific Antibody, Sars-cov-2 mutants, ADCs, Sars-cov-2 kits, Targets for CAR-T Cell Therapy, Multi-pass Transmembrane Proteins and Technology Platforms, Immune Checkpoint, Cytokine, BsAb targets, Fc Receptors, MABSOL Biotinylated Protein, Enzymes, Anti-idiotypic Antibodies, Cell Gene Therapy, and GMP grade Cytokines
Locations
Employees at ACROBiosystems
Updates
-
#MeetwithACRO [ACRO Event - US] 📍Day 1 at #AAPS2024 #PharmSci360 in Salt Lake City! Visit us at Booth #1209 to meet the team and discuss how ACRO can support your research! #recombinantproteins #tumortargets #ADC #residualdetectionkit #PharmSci360
-
-
#MeetwithACRO [ACRO Event - US] 🔬 We are excited to see everyone at #AAPS2024 #PharmSci360 next week in Salt Lake City! Visit us at Booth #1209 and to meet the team: Peter Hsueh, PhD., Lisa Chou ,Nikolas Kamachi , Sawyer De Keyser, and Max Y. to discuss how ACROBiosystems can accelerate your drug development progress! #recombinantproteins #tumortargets #ADC #residualdetectionkit #PharmSci360
-
-
#MeetwithACRO [ACRO Conference - Rome, Italy] ACROBiosystems is thrilled to meet you at ESGCT 2024 in Rome! Visit us at Booth #B31 to explore how our products can elevate your research and development efforts. Check out some of our cute giveaways at the booth, including our fan-favorite Llama Plush—yours to take home! #acrobiosystems #ESGCT #geneandcelltherapy
-
-
#ACROHighlights [Featured Product] 🌟 Exciting breakthroughs in lipid-lowering targeted therapies! 🌟 Recent advancements in PCSK9 drug development in China include 🔹 AstraZeneca's AZD0780 clinical trial approval (Sep 11) 🔹 Akeso's Inusimab market approval (Sep 30) 🔹 Hengrui’s REMAIN-1 study demonstrating significant LDL-C reduction (Oct 9) 🔹 Junshi's Angorisimab market approval (Oct 11) ACROBiosystems is proud to support drug development with key proteins such as PCSK9, ASGR1, LDL-R, and ASGR1 stable cells. Learn more about how our products accelerate progress: https://smpl.is/9qm69 #PCSK9 #LipidLowering #DrugDevelopment #Biopharma #ACROBiosystems #ClinicalTrials #Innovation
-
-
#MeetwithACRO [ACROVision Webinar Series] The next ACROVision Webinar, presented by Clarence DEFFAUD of BIOTEM First Class Antibodies & Immunoassays in collaboration with Medicen Paris Region, will take place on November 19 at 13:30 CET. Register now: https://lnkd.in/gEWcH9Gi Au cours des dernières décennies, les anticorps monoclonaux ont démontré leur efficacité dans divers domaines de la recherche, du diagnostic et en thérapeutiques. Cependant, leur taille est parfois apparue comme un facteur limitant dans certaines de leur application. Cette limitation est principalement due à l'incapacité de pénétrer d'atteindre le site d’intérêt. Les anticorps à domaine unique (single domain antibody), également connus sous le nom de VHH ou nanobody, sont réputés pour être des alternatives déjà efficaces dans quelques cas et des candidats prometteurs capables de remédier aux inconvénients des anticorps conventionnels de taille normale. Outre un niveau élevé d'affinité et de sélectivité vis-à-vis de leur cible, la petite taille des VHH (~15 kDa), leur capacité de pénétration tissulaire, leur grande stabilité, leur processus de fabrication simple et économique et leur demi-vie fugace dans le système circulatoire en ont fait des candidats prometteurs pour le développement de divers types de thérapies. Leurs propriétés font également des VHH un outil de choix pour des approches diagnostiques ou en recherche avec notamment la cristallographie. BIOTEM a extrait la quintessence de plus de trois décennies de connaissances sur les VHH et l'a combinée à une approche de pointe en matière de conception et de construction de bibliothèques de phage display pour développer Quinthetic LibraryTM, une banque synthétique exclusive de VHH avec un taux de réussite exceptionnel de 87%. #acrobiosystems #BIOTEM #Medicen
-
-
#MeetwithACRO [ACRO Conference - London, UK] Meet us at CELL 2024 in London! As proud sponsors, we invite you to visit our booth and join our scientific, exclusive ACROConnect Workshop to discuss current trends and challenges in Drug Model Innovation. Apply through the link below to attend and connect with expert Scientists from Charles River Laboratories, University College London, and fellow researchers plus complimentary access to the 3-day CELL & GENE 2024 conference! Location： Novotel London West, London, UK Date & Time： November 6th, 2024, 11:35AM - 1:30PM Register here: https://lnkd.in/gPYxFH2H #acrobiosystems #cell2024 #drugmodelinnovation
-
-
#MeetwithACRO [ACRO Conference - Basel, Switzerland] ACROBiosystems is thrilled to meet you at the Festival of Biologics 2024 in Basel! Visit us at Booth #520 to explore how our products can elevate your research and development efforts. Be sure to catch Dr. Anil Kumar's talk: "Driving Cell Therapy Success: ACRO's GMP Solutions for Seamless Manufacturing" on October 15th at 16:50. Don't miss our poster number 168: "Accelerating the development of novel antibody-drug conjugates through site-specific conjugation methods" presented by Dr. Hengshuo Liu. Check out some of our cute giveaways at the booth, including our fan-favorite Llama Plush—yours to take home! #ACROBiosystems #FestivalofBiologics #GMP #ADC
-
-
🌟 Groundbreaking Advance in Type 1 Diabetes Treatment: First Successful iPSC-Derived Islet Transplantation! A study published in Cell Press by Dr. Deng Hongkui’s team at Peking University marks a significant milestone in diabetes treatment. For the first time, researchers have successfully transplanted chemically induced pluripotent stem cell-derived (CiPSC) islets into a patient with Type 1 diabetes. Just 75 days post-transplantation, the patient achieved insulin independence, maintaining stable blood glucose levels without external insulin. ACROBiosystems is proud to support researchers in advancing groundbreaking stem cell therapies! ✅ Facilitate stem cell differentiation into endoderm, including beta islet cells and other cell types. ✅Ensure reliable, large-scale manufacturing capabilities. ✅Achieve cost efficiency, saving up to 50%. Discover our high-quality #ActivinA for efficient iPSC differentiation and take your research further! https://lnkd.in/gGGZ32iD #DiabetesResearch #StemCellTherapy #RegenerativeMedicine #MedicalBreakthrough #iPSC
-
Congratulations to the 2024 Nobel Prize in Chemistry Winners! 🏆 This year’s Nobel Prize in Chemistry has been awarded for groundbreaking work in utilizing #AI to reveal #ProteinStructures, a major leap in the field towards accelerates drug discovery, disease research, and advances biotechnology. With this milestone, AI-powered tools and high-quality proteins can work together to drive even faster breakthroughs in biopharmaceuticals. At ACROBiosystems, we’re thrilled to see AI's impact in advancing protein research and will continue elevating our recombinant proteins quality to support researchers in various fields. Let's celebrate this revolutionary step forward by sharing and commenting below on how proteins have helped your research and predict who will win the Nobel Prize next year! #NobelPrize #Chemistry #AdvancingDiscovery #RecombinantProteins
BREAKING NEWS The Royal Swedish Academy of Sciences has decided to award the 2024 Nobel Prize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.” The Nobel Prize in Chemistry 2024 is about proteins, life’s ingenious chemical tools. David Baker has succeeded with the almost impossible feat of building entirely new kinds of proteins. Demis Hassabis and John Jumper have developed an AI model to solve a 50-year-old problem: predicting proteins’ complex structures. These discoveries hold enormous potential. The diversity of life testifies to proteins’ amazing capacity as chemical tools. They control and drive all the chemical reactions that together are the basis of life. Proteins also function as hormones, signal substances, antibodies and the building blocks of different tissues. Proteins generally consist of 20 different amino acids, which can be described as life’s building blocks. In 2003, David Baker succeeded in using these blocks to design a new protein that was unlike any other protein. Since then, his research group has produced one imaginative protein creation after another, including proteins that can be used as pharmaceuticals, vaccines, nanomaterials and tiny sensors. The second discovery concerns the prediction of protein structures. In proteins, amino acids are linked together in long strings that fold up to make a three-dimensional structure, which is decisive for the protein’s function. Since the 1970s, researchers had tried to predict protein structures from amino acid sequences, but this was notoriously difficult. However, four years ago, there was a stunning breakthrough. In 2020, Demis Hassabis and John Jumper presented an AI model called AlphaFold2. With its help, they have been able to predict the structure of virtually all the 200 million proteins that researchers have identified. Since their breakthrough, AlphaFold2 has been used by more than two million people from 190 countries. Among a myriad of scientific applications, researchers can now better understand antibiotic resistance and create images of enzymes that can decompose plastic. Life could not exist without proteins. That we can now predict protein structures and design our own proteins confers the greatest benefit to humankind. Learn more Press release: https://bit.ly/3TM8oVs Popular information: https://bit.ly/3XYHZGp Advanced information: https://bit.ly/4ewMBta
-